miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer

He,Yue‑Jun; Wu,Jian‑Zhong; Ji,Ming‑Hua; Ma,Tao; Qiao,En‑Qi; Ma,Rong; Tang,Jin‑Hai

doi:10.3892/etm.2013.915

miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer

Authors:
- Yue‑Jun He
- Jian‑Zhong Wu
- Ming‑Hua Ji
- Tao Ma
- En‑Qi Qiao
- Rong Ma
- Jin‑Hai Tang
View Affiliations

Affiliations: Surgery Department, The Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 22100, P.R. China, Center Laboratory, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China, Radiotherapy Department, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China, Oncology Department of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China, Breast Surgery, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210000, P.R. China
Published online on: January 22, 2013 https://doi.org/10.3892/etm.2013.915
Pages: 813-818

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Estrogen receptor‑α (ERα) is essential for estrogen‑dependent growth and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα‑positive breast cancer. Breast cancer patients show a wide range of ERα expression levels which change in individual patients during disease progression and in response to systemic therapies. However, little is known concerning how the expression of ERα is regulated in human breast cancer. Recently, several microRNAs (miRNAs) have been identified to regulate ERα expression and to predict ER, progesterone receptor (PR) and human epidermal growth factor 2 (HER2) status. The expression levels of miR‑342 and ERα mRNA were analyzed in human breast cancer samples and cell lines by quantitative reverse transcription (RT)‑PCR analysis. The correlations between the expression levels of miR‑342 and clinicopathological factors were analyzed. Statistically significant associations were observed between miR‑342 and ER, HER2 and vascular endothelial growth factor (VEGF) status in the human breast cancer samples and the levels of miR‑342 gradually increased as ERα mRNA expression increased. Moreover, ectopic overexpression of miR‑342 upregulated the expression levels of the ERα mRNA and significantly sensitized the MCF‑7 cells to tamoxifen‑induced apoptosis and inhibition of cellular proliferation. These results suggested that miR‑342 expression is positively correlated with ERα mRNA expression in human breast cancer and that it may be a significant marker for predicting tamoxifen sensitivity in ERα‑positive breast cancer and a potential target for restoring ERα expression and responding to antiestrogen therapy.

View Figures

View References

1.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar
2.	Ford CH, Al-Bader M, Al-Ayadhi B and Francis I: Reassessment of estrogen receptor expression in human breast cancer cell lines. Anticancer Res. 31:521–527. 2011.PubMed/NCBI
3.	Wiechmann L, Sampson M, Stempel M, et al: Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 16:2705–2710. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Yamashita H, Ando Y, Nishio M, et al: Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 13:74–83. 2006. View Article : Google Scholar
5.	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
6.	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar
7.	Blenkiron C, Goldstein LD, Thorne NP, et al: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 8:R2142007. View Article : Google Scholar
8.	Lowery AJ, Miller N, Devaney A, et al: MicroRNA signatures predict estrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 11:R272009. View Article : Google Scholar : PubMed/NCBI
9.	Kondo N, Toyama T, Sugiura H, Fujii Y and Yamashita H: miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 68:5004–5008. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Adams BD, Furneaux H and White BA: The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 21:1132–1147. 2007. View Article : Google Scholar
11.	Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, et al: Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 28:3926–3936. 2009. View Article : Google Scholar
12.	Pandey DP and Picard D: miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol. 29:3783–3790. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, et al: An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J. 277:1684–1694. 2010. View Article : Google Scholar
14.	Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 283:31079–31086. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, et al: MicroRNA cluster 221–222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 102:706–721. 2010.
16.	Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD and Jones FE: Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 9:3172010. View Article : Google Scholar : PubMed/NCBI
17.	Bozzetti C, Nizzoli R, Guazzi A, Flora W, Bassano C, et al: HER2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol. 13:1398–1403. 2002. View Article : Google Scholar : PubMed/NCBI
18.	Obrero M, Yu DV and Shapiro DJ: Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem. 277:45695–45703. 2002. View Article : Google Scholar : PubMed/NCBI
19.	Lim LP, Lau NC, Garrett-Engele P, et al: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar
20.	Wang H, Wu J, Meng X, et al: MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 32:1033–1042. 2011. View Article : Google Scholar : PubMed/NCBI